Anemia in patients on combined androgen block therapy for prostate cancer.
- Author:
Li-Xin QIAN
1
;
Li-Xin HUA
;
Hong-Fei WU
;
Yuan-Geng SUI
;
Shuang-Guan CHENG
;
Wei ZHANG
;
Jie LI
;
Xin-Ru WANG
Author Information
- Publication Type:Journal Article
- MeSH: Adenocarcinoma; complications; drug therapy; therapy; Adult; Androgen Antagonists; adverse effects; therapeutic use; Anemia; chemically induced; Antineoplastic Agents, Hormonal; therapeutic use; Combined Modality Therapy; Flutamide; therapeutic use; Hematocrit; Hemoglobins; metabolism; Humans; Male; Orchiectomy; Prostatic Neoplasms; complications; drug therapy; therapy; Prostatic Secretory Proteins; analysis
- From: Asian Journal of Andrology 2004;6(4):383-384
- CountryChina
- Language:English
-
Abstract:
AIMTo study the effect of combined androgen block therapy on hemoglobin and hematocrit values in patients with prostate cancer.
METHODSOne hundred and thirty-six patients with adenocarcinoma of prostate were treated with combined androgen block (orchiectomy and flutamide 250 mg, tid). Complete blood counts were determined before and after 1, 2, 3, 6, 9 and 12 months of therapy.
RESULTSThe hemoglobin and hematocrit levels declined significantly in all patients and at all the time points after treatment (P<0.05).
CONCLUSIONProstate cancer patients treated with combined androgen block would develop obvious anemia. Recombinant human erythropoietin can be used to treat patients with severe anemia.
